Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 12

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 4
Chunk 12
---
Between
January and February 2020, the Deloitte Center for Health Solutions surveyed multiple leaders from 17 pharmaceutical companies on their
organizations’ RWE capabilities. Survey questions revolved around current and future applications for RWE, areas of investment,
strategic partnerships, and use of Real World Data (RWD) and RWE in R& D.

  Ninety-four                                                                                                                          
  percent of survey respondents believe using RWE in R& D will become important or very important to their organizations by 2022.      
  Almost                                                                                                                               
  all companies expect to increase investments in talent, technology, and external partnerships to strengthen their RWE capabilities.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Reduced                                                                                                                              
  Entered                                                                                                                              

  13  

The
Company believes it is very well positioned as a strategic partner and lead in this exciting growth sector. In addition, HealthTab™
is ideally situated to provide Real Time Real World Data (RTRWD). This is an important distinction from RWD because HealthTab™’s
anonymized data can be transmitted in real time versus the lag that is accompanied with RWD that is gathered from clinical reporting
systems, insurance claims and adverse event reporting systems.

Currently,
HealthTab™ is available in certain Shoppers Drug Marts in several Canadian provinces. The Company has secured commitments with
other pharmacies in Canada to place additional HealthTab™ systems and is in negotiations with corporate chains. Furthermore, the
Company expanded a partnership agreement with the Ontario Pharmacists Association (OPA) to endorse HealthTab™ to pharmacies conducting
COVID-19 testing and government for real-time reporting of test results. The OPA is the largest pharmacists’ association in the
country, with over 10,000 members and over 4,600 community pharmacy locations.

HealthTab™
is being embraced as it is the most credible way to deploy point-of-care testing in the pharmacy and community setting where it offers
the reliability, accuracy and flexibility the sector needs. Avricore has enjoyed a robust response from a variety of key industry players
including, CROs, labs, pharmacies and researchers and has been engaging in a variety of technical discussions which are anticipated to
lead to business.

As
conversations progress, the Company will be making announcements in due course.

Fully
Integrated Patient Health Records

The
Company has been in technical discussions on the integration of HealthTab™ into the electronic medical